Reliable and cost effective technique for detecting rheumatoid arthritis
Diagnosing rheumatoid arthritis (RA) in the early stages helps to get the treatment at the right time as soon as possible. With early diagnosis and proper treatment, it is possible to reduce the damage to the joints caused by RA. Deciding the most appropriate treatment for each patient at the earliest possible stage is central to effectively tackling this debilitating condition.
Rheumatoid arthritis can affect other parts of the body besides the joints. It can be difficult to diagnose in its early stages because the early signs and symptoms mimic those of many other diseases. There is no disease-specific serodiagnostic procedure to confirm the diagnosis and this has led to the generation of many serodiagnostic procedures based on the detection of autoantibodies reactive with various putative autoantigens. However, there are other types of procedures available to measure concentrations at high elevations of systemic biomarkers of inflammation. Acute phase reactants, cytokines/chemokines are widely used as objective indices of disease activity.
In this current review, researchers reported the findings of an epidemiological study of the prevalence of rheumatoid arthritis in a African population, in which the main focus was laid on biomarkers such as rheumatoid factor (RF), anti-citrullinated peptide (anti-CCP) and C-reactive protein have been shown to predate the clinical diagnosis of RA and even these are now recognised as one of the most reliable and cost-effective techniques in terms of diagnosing, predicting and monitoring the disease activity in RA patients.